FDA permits marketing of device to help reduce opioid withdrawal symptoms
On Nov. 15, the U.S. Food and Drug Administration (FDA) granted a new indication to an electric stimulation device (NSS-2 Bridge) for use in helping to reduce the symptoms of opioid withdrawal. Read more via Fda.gov.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.